{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T16:48:34Z","timestamp":1784047714164,"version":"3.55.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,7,17]],"date-time":"2017-07-17T00:00:00Z","timestamp":1500249600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s12016-017-8623-6","type":"journal-article","created":{"date-parts":[[2017,7,17]],"date-time":"2017-07-17T10:33:12Z","timestamp":1500287592000},"page":"234-243","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["The Comparative Safety of TNF Inhibitors in Ankylosing Spondylitis\u2014a Meta-Analysis Update of 14 Randomized Controlled Trials"],"prefix":"10.1007","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8410-5595","authenticated-orcid":false,"given":"Li-qiong","family":"Hou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga-xue","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-fei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi-Mei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-guang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi-chao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,17]]},"reference":[{"key":"8623_CR1","doi-asserted-by":"crossref","first-page":"961","DOI":"10.2147\/PPA.S33109","volume":"10","author":"JM Senabre","year":"2013","unstructured":"Senabre JM, Santos C, Santos G et al (2013) Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis. Patient Prefer Adherence 10:961\u2013972","journal-title":"Patient Prefer Adherence"},{"key":"8623_CR2","first-page":"2016","volume":"10","author":"D Wu","year":"2015","unstructured":"Wu D, Guo YY, Xu NN et al (2015) Efficacy of anti-tumor necrosis factor therapy for extra-articular manifestations in patients with ankylosing spondylitis: a meta-analysis. BMC Musculoskelet Disord 10:2016\u20132019","journal-title":"BMC Musculoskelet Disord"},{"key":"8623_CR3","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1007\/s00296-00013-02772-00296","volume":"33","author":"MA Machado","year":"2013","unstructured":"Machado MA, Barbosa MM, Almeida AM et al (2013) Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis. Rheumatol Int 33:2199\u20132213. doi:\n10.1007\/s00296-00013-02772-00296","journal-title":"Rheumatol Int"},{"key":"8623_CR4","doi-asserted-by":"crossref","first-page":"32768","DOI":"10.1038\/srep32768","volume":"10","author":"W Liu","year":"2016","unstructured":"Liu W, Wu YH, Zhang L et al (2016) Efficacy and safety of TNF-alpha inhibitors for active ankylosing spondylitis patients: multiple treatment comparisons in a network meta-analysis. Sci Rep 10:32768","journal-title":"Sci Rep"},{"key":"8623_CR5","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/art.23969","volume":"10","author":"RD Inman","year":"2008","unstructured":"Inman RD, Davis JC, Heijde D et al (2008) Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo- controlled, phase III trial. Arthritis Rheum 10:3402\u20133412","journal-title":"Arthritis Rheum"},{"key":"8623_CR6","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1136\/ard.2010.1392617","volume":"70","author":"M Dougados","year":"2011","unstructured":"Dougados M, Braun J, Szanto S et al (2011) Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE). Ann Rheum Dis 70:799\u2013804. doi:\n10.1136\/ard.2010.1392617","journal-title":"Ann Rheum Dis"},{"key":"8623_CR7","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1093\/rheumatology\/keu1132","volume":"53","author":"C Bao","year":"2014","unstructured":"Bao C, Huang F, Khan MA et al (2014) Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial. Rheumatology (Oxford) 53:1654\u20131663. doi:\n10.1093\/rheumatology\/keu1132","journal-title":"Rheumatology (Oxford)"},{"key":"8623_CR8","doi-asserted-by":"crossref","first-page":"380","DOI":"10.7326\/0003-4819-127-5-199709010-00008","volume":"127","author":"C Counsell","year":"1997","unstructured":"Counsell C (1997) Formulating questions and locating primary studies for inclusion in systematic reviews. Ann Intern Med 127:380\u2013387","journal-title":"Ann Intern Med"},{"key":"8623_CR9","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S Linden van der","year":"1984","unstructured":"van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361\u2013368","journal-title":"Arthritis Rheum"},{"key":"8623_CR10","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1177\/039463201102400136","volume":"24","author":"M Benucci","year":"2011","unstructured":"Benucci M, Saviola G, Baiardi P et al (2011) Efficacy and safety of leflunomide or methotrexate plus subcutaneous tumour necrosis factor-alpha blocking agents in rheumatoid arthritis. Int J Immunopathol Pharmacol 24:269\u2013274","journal-title":"Int J Immunopathol Pharmacol"},{"key":"8623_CR11","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1093\/rheumatology\/keq1123","volume":"49","author":"AD Billiau","year":"2010","unstructured":"Billiau AD, Loop M, Le P et al (2010) Etanercept improves linear growth and bone mass acquisition in MTX-resistant polyarticular-course juvenile idiopathic arthritis. Rheumatology (Oxford) 49:1550\u20131558. doi:\n10.1093\/rheumatology\/keq1123","journal-title":"Rheumatology (Oxford)"},{"key":"8623_CR12","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/03009740600844530","volume":"35","author":"H Bliddal","year":"2006","unstructured":"Bliddal H, Terslev L, Qvistgaard E et al (2006) A randomized, controlled study of a single intra-articular injection of etanercept or glucocorticosteroids in patients with rheumatoid arthritis. Scand J Rheumatol 35:341\u2013345","journal-title":"Scand J Rheumatol"},{"key":"8623_CR13","doi-asserted-by":"crossref","unstructured":"Blumenauer B, Judd M, Wells G et al (2002) Infliximab for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev 3","DOI":"10.1002\/14651858.CD003785"},{"key":"8623_CR14","first-page":"584","volume":"35","author":"M Boesen","year":"2008","unstructured":"Boesen M, Boesen L, Jensen KE et al (2008) Clinical outcome and imaging changes after intraarticular (IA) application of etanercept or methylprednisolone in rheumatoid arthritis: magnetic resonance imaging and ultrasound-Doppler show no effect of IA injections in the wrist after 4 weeks. J Rheumatol 35:584\u2013591","journal-title":"J Rheumatol"},{"key":"8623_CR15","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1136\/ard.2003.013961","volume":"63","author":"FC Breedveld","year":"2004","unstructured":"Breedveld FC, Emery P, Keystone E et al (2004) Infliximab in active early rheumatoid arthritis. Ann Rheum Dis 63:149\u2013155","journal-title":"Ann Rheum Dis"},{"key":"8623_CR16","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/ard.2003.017160","volume":"64","author":"FC Breedveld","year":"2004","unstructured":"Breedveld FC, Han C, Bala M et al (2004) Association between baseline radiographic damage and improvement in physical function after treatment of patients with rheumatoid arthritis. Ann Rheum Dis 64:52\u201355","journal-title":"Ann Rheum Dis"},{"key":"8623_CR17","first-page":"1035","volume":"36","author":"J Chang","year":"2007","unstructured":"Chang J, Girgis L (2007) Clinical use of anti-TNF-alpha biological agents\u2014a guide for GPs. Aust Fam Physician 36:1035\u20131038","journal-title":"Aust Fam Physician"},{"key":"8623_CR18","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1093\/rheumatology\/kep1239","volume":"48","author":"A Anis","year":"2009","unstructured":"Anis A, Zhang W, Emery P et al (2009) The effect of etanercept on work productivity in patients with early active rheumatoid arthritis: results from the COMET study. Rheumatology (Oxford) 48:1283\u20131289. doi:\n10.1093\/rheumatology\/kep1239","journal-title":"Rheumatology (Oxford)"},{"key":"8623_CR19","first-page":"243","volume-title":"Analysing data and undertaking meta-analyses","author":"JJ Deeks","year":"2008","unstructured":"Deeks JJ, Higgins J, Altman DG (2008) Analysing data and undertaking meta-analyses. Cochrane Handbook for Systematic Reviews of Interventions, Cochrane Book Series, pp 243\u2013296"},{"key":"8623_CR20","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ et al (2003) Measuring inconsistency in meta-analyses. BMJ 327:557\u2013560","journal-title":"BMJ"},{"key":"8623_CR21","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539\u20131558","journal-title":"Stat Med"},{"key":"8623_CR22","first-page":"2080","volume":"10","author":"BC Wallace","year":"2009","unstructured":"Wallace BC, Schmid CH, Lau J et al (2009) Meta-analyst: software for meta-analysis of binary, continuous and diagnostic data. BMC Med Res Methodol 10:2080","journal-title":"BMC Med Res Methodol"},{"key":"8623_CR23","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","volume":"359","author":"J Braun","year":"2002","unstructured":"Braun J, Brandt J, Listing J et al (2002) Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359:1187\u20131193","journal-title":"Lancet"},{"key":"8623_CR24","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJMoa012664","volume":"346","author":"JD Gorman","year":"2002","unstructured":"Gorman JD, Sack KE, Davis JC et al (2002) Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 346:1349\u20131356","journal-title":"N Engl J Med"},{"key":"8623_CR25","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/art.11325","volume":"48","author":"JC Davis","year":"2003","unstructured":"Davis JC, Van Der Heijde D, Braun J et al (2003) Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 48:3230\u20133236","journal-title":"Arthritis Rheum"},{"key":"8623_CR26","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","volume":"52","author":"D Heijde van der","year":"2005","unstructured":"van der Heijde D, Dijkmans B, Geusens P et al (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52:582\u2013591","journal-title":"Arthritis Rheum"},{"key":"8623_CR27","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1136\/ard.2004.020875","volume":"2063","author":"A Calin","year":"2004","unstructured":"Calin A, Dijkmans BA, Emery P et al (2004) Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2063:1594\u20132600","journal-title":"Ann Rheum Dis"},{"key":"8623_CR28","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1136\/ard.2004.022582","volume":"64","author":"H Marzo","year":"2005","unstructured":"Marzo H, McGonagle D, Jarrett S et al (2005) Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. Ann Rheum Dis 64:1568\u20131575","journal-title":"Ann Rheum Dis"},{"key":"8623_CR29","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","volume":"54","author":"D Heijde van der","year":"2006","unstructured":"van der Heijde D, Kivitz A, Schiff MH et al (2006) Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54:2136\u20132146","journal-title":"Arthritis Rheum"},{"key":"8623_CR30","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1136\/ard.2006.056747","volume":"65","author":"D Heijde van der","year":"2006","unstructured":"van der Heijde D, Da Silva JC, Dougados M et al (2006) Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. Ann Rheum Dis 65:1572\u20131577","journal-title":"Ann Rheum Dis"},{"key":"8623_CR31","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1136\/ard.2009.121327","volume":"69","author":"N Barkham","year":"2010","unstructured":"Barkham N, Coates LC, Keen H et al (2010) Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis. Ann Rheum Dis 69:1926\u20131928. doi:\n10.1136\/ard.2009.121327","journal-title":"Ann Rheum Dis"},{"key":"8623_CR32","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1136\/annrheumdis-2012-202533","volume":"73","author":"F Huang","year":"2014","unstructured":"Huang F, Gu J, Zhu P et al (2014) Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial. Ann Rheum Dis 73:587\u2013594. doi:\n10.1136\/annrheumdis-2012-202533","journal-title":"Ann Rheum Dis"},{"key":"8623_CR33","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/art.30223","volume":"63","author":"J Braun","year":"2011","unstructured":"Braun J, van der Horst IE, Huang F et al (2011) Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum 63:1543\u20131551","journal-title":"Arthritis Rheum"},{"key":"8623_CR34","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1002\/art.11017","volume":"48","author":"J Brandt","year":"2003","unstructured":"Brandt J, Khariouzov A, Listing J et al (2003) Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 48:1667\u20131675","journal-title":"Arthritis Rheum"},{"key":"8623_CR35","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1136\/ard.2003.016717","volume":"63","author":"J Brandt","year":"2004","unstructured":"Brandt J, Listing J, Sieper J et al (2004) Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis. Ann Rheum Dis 63:1438\u20131344","journal-title":"Ann Rheum Dis"},{"key":"8623_CR36","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.3899\/jrheum.081033","volume":"36","author":"B Dijkmans","year":"2009","unstructured":"Dijkmans B, Emery P, Hakala M et al (2009) Etanercept in the longterm treatment of patients with ankylosing spondylitis. J Rheumatol 36:1256\u20131264. doi:\n10.3899\/jrheum.081033","journal-title":"J Rheumatol"},{"key":"8623_CR37","doi-asserted-by":"publisher","unstructured":"Inman RD, Maksymowych WP (2010) A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis. J Rheumatol (37):1203\u20131210. doi:\n10.3899\/jrheum.091042","DOI":"10.3899\/jrheum.091042"},{"key":"8623_CR38","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1136\/ard.2008.098822","volume":"69","author":"A Fouque","year":"2010","unstructured":"Fouque A, Jette L, Combescure C et al (2010) Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta-analysis of randomised placebo-controlled trials. Ann Rheum Dis 69:1756\u20131761. doi:\n10.1136\/ard.2008.098822","journal-title":"Ann Rheum Dis"},{"key":"8623_CR39","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1136\/ard.62.9.829","volume":"62","author":"D Baeten","year":"2003","unstructured":"Baeten D, Kruithof E, Van den Bosch F et al (2003) Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis 62:829\u2013834","journal-title":"Ann Rheum Dis"},{"key":"8623_CR40","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1136\/ard.2004.033993","volume":"64","author":"J Askling","year":"2005","unstructured":"Askling J, Fored CM, Brandt L et al (2005) Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 64:1421\u20131426","journal-title":"Ann Rheum Dis"},{"key":"8623_CR41","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1136\/ard.2008.102103","volume":"68","author":"GR Burmester","year":"2009","unstructured":"Burmester GR, Mease P, Dijkmans BA et al (2009) Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis 68:1863\u20131869. doi:\n10.1136\/ard.2008.102103","journal-title":"Ann Rheum Dis"},{"key":"8623_CR42","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/art.24506","volume":"61","author":"C Nannini","year":"2009","unstructured":"Nannini C, Cantini F, Niccoli L et al (2009) Single-center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor alpha therapy: is there a need for more comprehensive screening procedures? Arthritis Rheum 61:801\u2013812","journal-title":"Arthritis Rheum"}],"container-title":["Clinical Reviews in Allergy &amp; Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12016-017-8623-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-017-8623-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-017-8623-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T08:09:52Z","timestamp":1535011792000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12016-017-8623-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,17]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["8623"],"URL":"https:\/\/doi.org\/10.1007\/s12016-017-8623-6","relation":{},"ISSN":["1080-0549","1559-0267"],"issn-type":[{"value":"1080-0549","type":"print"},{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,17]]}}}